Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07819474 | Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With | not yet recruiting | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 |
| clinicaltrials |
| NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.(SIGNAL-IO 301) | not yet recruiting | N/A | 920 | Natera, Inc.INDUSTRY | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07740642 | A Comparative Usability Study of Two Total Body Skin Imaging Systems | not yet recruiting | N/A | 60 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05004792 | Dermoscopy Augmented Histology Trial, a Randomized Controlled Trial(DAHT-RCT) | not yet recruiting | N/A | 258 | Herlev HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07529080 | Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial | not yet recruiting | N/A | 142 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07660666 | Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor | not yet recruiting | N/A | 50 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07653087 | Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma(Mel73) | not yet recruiting | N/A | 66 | University of VirginiaOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07114172 | Study of Melanoma-Resistant PET Monitoring Based on Key Rate-limiting Enzymes for Fatty Acid Metabolism in Healthy Volunteers | not yet recruiting | N/A | 15 | Xijing HospitalOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT07028008 | Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors | not yet recruiting | N/A | 9 | Samsung Medical CenterOTHER | 0 | Jun 26, 2025 | clinicaltrials |
| NCT06553781 | A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma | not yet recruiting | N/A | 28 | Fudan UniversityOTHER | 0 | Aug 14, 2024 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials